Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GILL L FREI

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1477541761
CMS profile
157806
Location
BRONX, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$176.17

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $176.17 9

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GILL L FREI

NPI 1477541761 · CMS profile ID 157806

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

BRONX, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477541761?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GILL L FREI, NPI 1477541761, CMS profile ID 157806. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477541761?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GILL L FREI, NPI 1477541761, CMS profile ID 157806. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477541761?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GILL L FREI, NPI 1477541761, CMS profile ID 157806, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1477541761?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $176.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $22.5011/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915855919 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.2411/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929979317 CMS
Novo Nordisk Inc $20.0609/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899000950 CMS
Novo Nordisk Inc $18.0609/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899048367 CMS
AKEBIA THERAPEUTICS INC $20.4109/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885306353 CMS
AKEBIA THERAPEUTICS INC $17.6307/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885306311 CMS
Vifor Pharma, Inc. $12.4406/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896764841 CMS
Novo Nordisk Inc $21.4205/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898903012 CMS
Aurinia Pharma U.S., Inc. $21.4103/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954076497 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $873.01 41
PY2020 $384.55 19
PY2021 $465.75 23
PY2022 $176.17 9
PY2023 $271.66 13
PY2024 $340.49 14
PY2025 $559.27 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $6,555.00 5
PY2020 Principal investigator $68,056.25 24
PY2019 Principal investigator $110,031.15 206

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $9,000.00 11/20/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753286785
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,500.00 08/03/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753285979
Principal investigator 1 AKEBIA THERAPEUTICS INC $240.00 06/11/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753284637
Principal investigator 1 AKEBIA THERAPEUTICS INC $480.00 06/10/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753284615
Principal investigator 1 AKEBIA THERAPEUTICS INC $760.33 05/18/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753283987
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,000.00 05/12/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753283813
Principal investigator 1 AKEBIA THERAPEUTICS INC $750.00 04/16/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753283131
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,265.00 04/07/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753282897
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,099.00 04/01/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753282521
Principal investigator 1 AKEBIA THERAPEUTICS INC $290.92 03/26/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289755
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 03/24/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289959
Principal investigator 1 AKEBIA THERAPEUTICS INC $576.24 02/28/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289931
Principal investigator 1 AKEBIA THERAPEUTICS INC $387.00 02/25/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753289357
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 02/25/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289375
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 02/25/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289925
Principal investigator 1 AKEBIA THERAPEUTICS INC $152.00 02/24/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289161
Principal investigator 1 AKEBIA THERAPEUTICS INC $456.20 02/14/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289891
Principal investigator 1 AKEBIA THERAPEUTICS INC $480.00 02/07/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289875
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 01/30/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289817
Principal investigator 1 AKEBIA THERAPEUTICS INC $140.00 01/24/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289801
Principal investigator 1 AKEBIA THERAPEUTICS INC $7,382.00 01/09/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753287411
Principal investigator 1 AKEBIA THERAPEUTICS INC $34,145.00 01/08/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753282451
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 01/03/2020 Non-covered Recipient Entity
KIDNEY MEDICAL ASSOCIATES, PLLC
PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) No dispute reported 06/30/2026 753289781
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,778.00 01/02/2020 Non-covered Recipient Entity
TOTAL RENAL RESEARCH INC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753287349